The parkin was first identified as a gene implicated in autosomal recessive juvenile Parkinsonism. Deregulation of the parkin gene, however, has been observed in various human cancers, suggesting that the parkin gene may be important in tumorigenesis. To gain insight into the physiologic role of parkin, we generated parkinÀ/À mice lacking exon 3 of the parkin gene. We demonstrated here that parkinÀ/À mice had enhanced hepatocyte proliferation and developed macroscopic hepatic tumors with the characteristics of hepatocellular carcinoma. Microarray analyses revealed that parkin deficiency caused the alteration of gene expression profiles in the liver. Among them, endogenous follistatin is commonly upregulated in both nontumorous and tumorous liver tissues of parkindeficient mice. Parkin deficiency resulted in suppression of caspase activation and rendered hepatocytes resistant to apoptosis in a follistatin-dependent manner. These results suggested that parkin deficiency caused enhanced hepatocyte proliferation and resistance to apoptosis, resulting in hepatic tumor development, partially through the upregulation of endogenous follistatin. The finding that parkindeficient mice are susceptible to hepatocarcinogenesis provided the first evidence showing that parkin is indeed a tumor suppressor gene.
Introduction
The parkin was first identified as a gene implicated in autosomal recessive juvenile Parkinsonism (ARJP), the most frequent form of familial Parkinson disease (Farrer, 2006) . Mutations in the parkin gene have been found among ARJP families worldwide (Kitada et al., 1998) . Parkin protein is characterized by a ubiquitin-like domain at the N terminus and two RING-finger motifs and in between RING-finger (IBR) motif at the C terminus (Kahle and Haass, 2004) . There are an increasing number of studies, including ours, showing that parkin is an E3 ubiquitin ligase that targets a variety of candidate substrate proteins, resulting in proteosomal degradation (Jackson et al., 2000; Shimura et al., 2000; Takahashi et al., 2003) . Possible substrates for parkin include: o-glycosylated a-synphilin; a-synuclein interacting protein, synphilin-1 and Pael-R (Dawson and Dawson, 2003) . These substrates suggest crucial roles for parkin in several cellular processes. However, the physiological role of parkin, especially in organs other than the brain, has not been clarified.
Human cancer develops through a multistep process involving the accumulation of genetic alterations that drive the progression of normal cells into malignant derivatives (Lengauer et al., 1998) . It has been shown that the development of human cancers can be triggered by various allelic deletions, which could theoretically contain tumor suppressor genes. Indeed, many tumors are associated with deletion of chromosomal regions containing the tumor suppressors p53 and Rb (Hahn and Weinberg, 2002) . One thing to be noted is that the loss of heterozygosity (LOH) within chromosomal region 6q25-q27 is frequently associated with various types of solid tumor, including carcinomas of the ovary (Saito et al., 1996; Tibiletti et al., 1996) , breast (Rodriguez et al., 2000) , kidney (Morita et al., 1991) , lung (Kong et al., 2000) and melanomas (Millikin et al., 1991) . On the other hand, the transfer of human chromosome 6 to melanoma cells resulted in the loss of their ability to form tumors in nude mice (Trent et al., 1990) . Moreover, normal chromosome 6 altered tumor growth properties in vitro and suppressed the tumorigenicity of breast cancer cells (Negrini et al., 1994) . These findings suggest that undefined genes present in chromosome 6 may play roles as tumor suppressor genes. Recently, physical mapping combined with LOH analysis identified parkin as a possible tumor suppressor gene, as the chromosomal region containing the highly unstable FRA6E common fragile site region at 6q25-q27 is frequently deleted in breast and ovarian tumors (Cesari et al., 2003; Denison et al., 2003) . In addition, another study reported that 4 of 11 hepatocellular carcinoma (HCC) cell lines had heterozygous deletion of parkin exon, and that parkin protein expression was significantly decreased or absent in all 11 HCC cells (Wang et al., 2004) . These findings suggest that parkin is important as a tumor suppressor and is involved in the development of human cancers. To gain insight into the physiological and pathological role of parkin, we generated parkinÀ/À mice and analysed their phenotypes.
Results
Development of hepatocellular carcinoma in parkinÀ/À mice The mutant parkin allele lacking exon 3 was generated by homologous recombination in murine AK18.1 ES cells (129S4/SvJaeSor), and the parkin mutation was maintained in a mixed 129/C57BL6SJL (75/25) genetic background (Kitao et al., 2007) . ParkinÀ/À mice were born alive and appeared healthy, but body weight was significantly reduced in both male and female parkinÀ/À mice compared to wild-type mice (31.77±0.72 g for parkinÀ/À male mice vs 36.23 ± 0.58 g for wild-type male mice at 48 weeks of age; n ¼ 42 for each; Figure 1a ). ParkinÀ/À mice were neurologically normal with no obvious behavioral abnormalities, and no neuropathologic changes were observed in aged parkinÀ/À mice, which is consistent with recent reports (Goldberg et al., 2003; Itier et al., 2003; Palacino et al., 2004; Von Coelln et al., 2004; Perez and Palmiter, 2005) . In contrast to the lack of neuropathologic abnormalities, a striking phenotypic change occurred in the livers of parkinÀ/À mice. Despite the low body weight of parkinÀ/À mice, their livers were enlarged: at 48 weeks of age, their liver weight was 1.5 times greater than that of wild-type mice (1.55 ± 0.24 vs 1.09 ± 0.34 g; Figure 1b ). Thus, the ratio between liver weight and body weight of parkinÀ/À mice was about twofold greater than that of wild-type mice at 48 weeks of age.
The livers of aged parkinÀ/À mice had a distinct phenotype. In addition to hepatomegaly, macroscopic hepatic tumors developed in 33% (12/36) and 45% (19/42) of parkinÀ/À mice at 72 and 96 weeks of age, respectively. In contrast to the parkinÀ/À mice, no hepatic tumors were admitted in the wild-type and parkin þ /-mice examined at the same age. Histological examination revealed that these tumors were trabeculartype liver cancers, which were similar to human HCC (Figure 2a ). It is noteworthy that all HCC tissues examined expressed a-fetoprotein (AFP), the best known tumor marker for human HCC, whereas no AFP expression was observed in the nontumorous regions of either parkinÀ/À livers or wild-type livers (Figure 2b ). Moreover, strong immunoreactivity for b-catenin was observed in HCC tissues of the parkinÀ/À mice, whereas staining for b-catenin was absent in the nontumorous region of the parkin-deficient liver (Figure 2c ).
Gene expression profiles in nontumorous and tumorous liver tissues of parkinÀ/À mice Consistent with previously reported parkinÀ/À mice models (Goldberg et al., 2003) , immunoblot analyses revealed no significant changes in the expression levels of several parkin substrate proteins (data not shown). On the other hand, it has been demonstrated that parkin has a RING-IBR-RING motif, which has been predicted to be involved in the regulation of gene expression (Morett and Bork, 1999) . To provide an insight into the molecular mechanism by which parkin deficiency contributes to hepatocarcinogenesis, we analysed gene expression profiles of nontumorous and tumorous liver tissues from parkinÀ/À mice using cDNA microarray analyses. Out of 43 800 genes analysed, we identified a number of genes that were upregulated or downregulated in the liver tissues of parkinÀ/À mice. Among them, the expression ratios of 302 genes (including 59 genes of unknown function) were greater than fivefold in the tumorous liver tissues compared to those in normal livers of wild-type mice (Supplementary Table 1 ). Similarly, we identified 96 genes (including 31 genes of unknown function) that were upregulated in nontumorous liver tissues of parkinÀ/À mice compared to liver tissues of wild-type Table 2 ). To identify the key molecule responsible for enhanced hepatocyte proliferation, and thus hepatocarcinogenesis, in parkinÀ/À mice, we searched for genes that were commonly upregulated in both nontumorous and tumorous liver tissues of the parkinÀ/À mice. This ensured that the genes selected were not confined to nontumorous or to tumorous tissues. Using this filter, we identified 13 genes that were commonly upregulated in livers of parkinÀ/À mice (Table 1) . These 13 upregulated genes included those expressing enzymes (cytochrome p450 (4a10), abhydrolase domain containing 1, hydroxysteroid dehydrogenase-4 and asparagine synthetase), molecules involved in metabolism, chemokine ligand 1 and the activinantagonist, follistatin. The filter also identified genes that were downregulated in nontumorous (104 genes) and tumorous liver tissues (138 genes) of parkinÀ/À mice whose expression ratio was less than fivefold than those of corresponding genes in normal liver. Among them, 17 genes were commonly downregulated in both nontumorous and tumorous liver tissues of the parkinÀ/À mice (Supplementary Table 3) , however, the role of these genes in tumorigenesis is unclear at present. The microarray data have been submitted to the Gene Expression Omnibus (GEO) public database at National Center for Biotechnology Information (NCBI) under the accession number GSE9651.
Upregulation of endogenous follistatin in parkinÀ/À mice Follistatin is an endogenous antagonist of activin and controls proliferation, differentiation and apoptosis of numerous cell types in an autocrine and paracrine manner (Chen et al., 2002; Harrison et al., 2005) . Recent studies demonstrated that overexpression of follistatin is associated with enhanced hepatocyte proliferation, resulting in enlargement of the liver in vivo (Kogure et al., 2000; Takabe et al., 2003) . As follistatin expression is commonly upregulated in the livers of parkinÀ/À mice, we focused on the hepatic expression of follistatin to clarify the mechanism by which parkin deficiency causes HCC. To confirm the reliability of microarray data, we first examined the expression of follistatin using semiquantitative and quantitative real-time RT-PCR assays with primers specific for mouse follistatin. Expression of b-actin and 18S rRNA transcripts served as internal controls. Although transcription of follistatin was low in the normal livers of wild-type mice, expression of follistatin was substantially upregulated in both tumorous and nontumorous liver tissues of parkinÀ/À mice ( Figure 3a) . Transcripts of the transforming growth factor-b superfamily genes in liver tissues, including the genes for inhibin-A, inhibin-B, BMP2 and BMP4, were also examined, but there were no differences in their expression between wild-type and parkinÀ/À mice ( Figure 3b ). To further confirm the upregulation of follistatin expression in parkinÀ/À mice, we performed immunoblot analyses using antibodies specific for follistatin. The follistatin protein was not detected in lysates from liver tissues of wild-type mice. In contrast, follistatin protein was clearly detectable in the tumorous liver tissues of parkinÀ/À mice (Figure 3c ), consistent with the data obtained from the quantitative real-time RT-PCR analyses. To examine the tissue-specific expression of follistatin, total RNA samples extracted from wild-type and parkinÀ/À mice tissues (liver, kidney, lung, small intestine and brain) were analysed using quantitative real-time RT-PCR. We found that follistatin mRNA was highly expressed in the livers of parkinÀ/À mice, whereas substantially lower levels of follistatin expression were observed in various tissues of the wild-type mice and in the liver of the parkin þ /-mice ( Figure 3d ).
To determine whether parkin is involved in transcriptional regulation of follistatin, we examined the effect of parkin on expression of endogenous follistatin using cultured hepatoma-derived cells. First, we confirmed that follistatin protein expression was markedly decreased in Hep3B cells with parkin expression Figure 1a) . Quantitative real-time RT-PCR analyses revealed that overexpression of parkin in cultured hepatoma-derived cells resulted in the substantial downregulation of follistatin expression, whereas mutant parkin lacking exons 3-4 had no significant effects on the expression of follistatin Genes that were upregulated in both nontumorous and tumorous liver tissues of parkin-/-mice whose expression ratio was greater than fivefold compared to normal livers of wild-type mice are shown. The lower graphs show the relative mRNA levels of follistatin measured by quantitative real-time RT-PCR using 18S rRNA as an internal control (mean ± s.d.; n ¼ 3). *P-value of o0.05 as determined by Student's t-test. (b) Total RNA was isolated from the liver tissues of wild-type ( þ / þ ), NT and T liver tissues of parkinÀ/À mice. RT-PCR was performed using 0.5 mg of each RNA as a template and oligonucleotide primer sets specific for mice inhibin-A, inhibin-B, BMP2, BMP4 and b-actin. (c) Total protein was isolated, and immunoblot analyses were carried out using anti-Fst (upper panel) or anti-b-actin (lower panel) in the livers of wild-type ( þ / þ ), NT and T liver tissues of parkinÀ/À mice. (d) Expression levels of endogenous follistatin in various organs. Quantitative real-time RT-PCR was carried out using the total RNA isolated from the various organs of wild-type ( þ / þ , open bars) and parkinÀ/À mice (black bars). The expression levels of Fst transcripts in the liver of the parkin þ /-are also shown as a gray bar.
(Supplementary Figure 1b) . Moreover, expression of parkin in Huh7 cells resulted in dose-dependent reductions in the relative amounts of follistatin transcripts (Supplementary Figure 1c) . Use of reporter plasmids encoding the promoter region of the follistatin gene revealed that parkin expression resulted in a substantial decrease in luciferase activity in the transfected cells (Supplementary Figure 1d) . Finally, we investigated the expression profiles of follistatin as well as the parkin gene in clinical specimens of human HCC tissues. We found that most of the liver cancer specimens that lacked parkin expression showed upregulation of follistatin compared to the nontumorous region of the liver (Supplementary Figure 2a) . In contrast, human HCC specimens that had a parkin expression level similar to the nontumorous regions did not show such enhanced expression of follistatin transcripts (Supplementary Figure 2b) . Taken together, these findings indicate that the expression of follistatin was specifically elevated in the parkin-deficient livers and suggest that parkin is involved in the transcriptional regulation of follistatin expression in hepatocytes.
Parkin deficiency comprising follistatin upregulation renders hepatocytes more resistant to apoptosis To investigate the molecular basis of hepatomegaly in parkinÀ/À mice, hepatocyte proliferation rate was determined using PCNA (proliferating cell nuclear antigen) labeling. Consistent with the development of hepatomegaly, enhanced hepatocyte proliferation was observed in the livers of 48-week-old parkinÀ/À mice (Figure 4a ). Increased proliferation of parkinÀ/À hepatocytes was further supported by 5-bromodeoxyuridine (BrdU) labeling of primary hepatocytes, which showed that hepatocyte growth factor (HGF) stimulation resulted in a higher level of BrdU labeling in parkinÀ/À hepatocytes than in those of wild-type mice (Figure 4b ). To clarify the functional significance of follistatin upregulation, we investigated whether parkindeficient hepatocytes are resistant to apoptosis because of upregulation of follistatin. To determine whether caspase activation is suppressed in parkin-deficient hepatocytes, cytosolic extracts from the livers of parkinÀ/À and wild-type mice were prepared, normalized for total protein content and then treated with either cytochrome c or granzyme B. In control extracts (b) 5-Bromodeoxyuridine (BrdU) labeling on the primary hepatocytes before and after the treatment with hepatocyte growth factor (HGF). Mouse primary hepatocytes were established from parkinÀ/À or wild-type ( þ / þ ) mice and cultured in fresh medium for 24 h, followed by the treatment with recombinant HGF (10 ng/ml) for 48 h. The levels of BrdU labeling were determined by flow cytometric analyses. (c) Parkin deficiency caused an overall inhibition of caspase activation induced by cytochrome c (Cyt-c) and granzyme B (Gra-B). Lysates were prepared from liver specimens of wild-type ( þ / þ ), parkinÀ/À mice and normalized for total protein content. Caspase activity was measured using the caspase-3 substrate, Ac-DEVD-pNA (10 mM), after the addition of Cyt-c and dATP (left graph) or Gra-B (right graph). Results are expressed relative to caspase activity generated in the normal liver of wild-type mice (mean ± s.d.; n ¼ 3). Reaction mixture without Cyt-c or Gra-B was included as a negative control (NC). *P-value of o0.05 as determined by Student's t-test. (d, e) ParkinÀ/À hepatocytes show resistance to apoptosis induced by various anticancer drugs. Primary hepatocytes were established from wild-type ( þ / þ ) or parkinÀ/À mice. Then, cells were treated for 48 h with 200 mM cisplatin (CDDP), 10 mM doxorubicin (DOX) or 400 nM etoposide (VP-16). Cell viability was determined by a trypan blue dye exclusion assay (d) and Annexin-V staining (e) (mean±s.d.; n ¼ 3). The percentage of apoptotic cells was determined from >200 cells, manually counted in triplicate. *P-value of o0.05 as determined by Student's t-test.
Parkin as a tumor suppressor gene M Fujiwara et al from wild-type mice, cytochrome c or granzyme B induced the activation of caspases, as measured by cleavage of the caspase substrate, Ac-DEVD-pNA. By comparison, far less caspase activity was induced by cytochrome c or granzyme B in extracts prepared from parkinÀ/À livers (Figure 4c ). To investigate the antiapoptotic features of parkinÀ/À hepatocytes, we established cultured primary hepatocytes from parkinÀ/À mice and compared levels of apoptosis induced by cisplatin (CDDP), doxorubicin (DOX) or etoposide (VP-16) between parkinÀ/À hepatocytes and wild-type cells. As shown in Figure 4d , significantly less cell death was induced by CDDP, DOX or VP-16 in the parkinÀ/À hepatocytes compared to the normal hepatocytes, consistent with the finding that parkin deficiency caused suppression of caspase activation. Annexin-V assay revealed significantly reduced numbers of apoptotic parkinÀ/À hepatocytes after treatment with DOX compared to those of the hepatocytes derived from the wild-type mice (Figure 4e ). To determine whether upregulation of follistatin is involved in reducing apoptosis in parkinÀ/À cells, we used small-interfering RNA (siRNA) to inhibit the expression of endogenous follistatin in primary mouse hepatocytes. Induction of follistatin-specific, but not control, double-strand synthetic RNAs reduced endogenous follistatin transcript levels in both normal and parkinÀ/À mouse hepatocytes, although only trace amounts of follistatin were detectable in hepatocytes derived from wild-type mice (Figure 5a ). In the primary hepatocytes derived from parkinÀ/À mice, treatment with DOX was more effective in inducing apoptosis in hepatocytes treated with follistatin siRNA compared to those treated with control siRNA (Figure 5b) . In contrast, a far less suppressive effect of knockdown of endogenous follistatin was observed on apoptosis of normal hepatocytes. These findings suggest that upregulation of follistatin is closely associated with suppression of caspase activation and apoptosis in parkinÀ/À hepatocytes.
Discussion
The molecular events underlying the development of human HCC are not well understood. However, it is believed that a multistep process of genetic alterations is responsible for hepatocarcinogenesis (Feitelson et al., 2002; Laurent-Puig and Zucman-Rossi, 2006) . The development and progression of cancers is characterized by inactivation of tumor suppressor genes and by amplification of selected oncogenes (Farazi and DePinho, 2006) . Although several transgenic mouse models have been shown to develop liver cancers, the key tumor suppressor molecules involved in hepatocarcinogenesis are unclear. In the present study, we demonstrated for the first time that parkin is important in the regulation of hepatocyte proliferation and apoptosis, and that the loss of parkin expression results in the development of HCC. There is a paucity of data on whether genes associated with Parkinson's disease are important in the biochemical pathways essential for carcinogenesis (West et al., 2005) . In contrast to epidemiologic studies indicating a negative association between Parkinson's disease and cancer, recent reports suggest that parkin is involved in the development of various human cancers (Cesari et al., 2003; Denison et al., 2003; Picchio et al., 2004; Wang et al., 2004) . Our present findings, which show that parkinÀ/À mice are susceptible to HCC, provided the evidence suggesting that parkin is important as a tumor suppressor gene.
Several other groups independently generated parkinÀ/À mice with various targeted deletions of the parkin gene (Goldberg et al., 2003; Itier et al., 2003; Palacino et al., 2004; Von Coelln et al., 2004; Perez and Palmiter, 2005) . Two groups described exon 3-deleted mice models similar to ours and reported that they had no dopaminergic neuronal loss (Goldberg et al., 2003; Palacino et al., 2004) . A recent report also demonstrated negligible deficits in neurological function, learning or memory in exon 2-deleted models (Perez and Palmiter, 2005) . These findings suggest that parkinÀ/À mice do not recapitulate signs central to Parkinsonism. However, all these previous studies focused on phenotypic analyses of the central nervous system. It is thus unclear whether these parkinÀ/À mice developed hepatic tumors. Given that other parkinÀ/À mice did not develop HCC, the inconsistent phenotype observed by different laboratories might be due to differences in the genetic backgrounds of strains. Alternatively, the discrepancy between our results and those of others may have arisen from the timing of the analyses for the liver phenotype. Our parkinÀ/À mice model showed no evidence of hepatic tumors at 48 weeks. The majority of tumors were detected at an age of 72 weeks or older, whereas some of the previous analyses of parkinÀ/À mice were carried out when the mice were less than 72 weeks of age (Goldberg et al., 2003; Palacino et al., 2004) . Further analyses are necessary to determine whether parkin deficiency is always responsible for enhanced hepatocyte proliferation and the development of HCC in various parkinÀ/À mouse models. In contrast to hepatomegaly, we found that the body weight of the parkinÀ/À mice was significantly lower than the wild-type mice by unknown reason. One possibility is to assume that changes in the levels of metabolism-related molecules were involved in the low body weights of parkinÀ/À mice.
Importantly, we demonstrated that follistatin is commonly upregulated in both nontumorous and tumorous liver tissues of parkinÀ/À mice. Our findings also showed that parkin expression resulted in the decrease in the expression levels of follistatin transcripts in vitro. The molecular mechanism responsible for regulation of follistatin transcription by parkin is unclear at present. However, it was shown that parkin regulates the gene transcription of monoamine oxidase in various cells (Jiang et al., 2006) . It is of note that the ability of parkin to suppress monoamine oxidase expression does not appear to be dependent on its ubiquitin ligase activity. Parc, a parkin-like ubiquitin ligase, also has a RING-IBR-RING motif and acts as a cytoplasmic anchor for the p53 protein, resulting in suppression of p53 gene-dependent transcription (Nikolaev et al., 2003) . In the current study, reporter plasmid assay revealed that parkin expression induced the substantial decrease of promoter activity of follistatin gene. Thus, it might be possible to assume that parkin is involved in the transcriptional regulation of follistatin gene expression, either independent of its E3 ligase function or by the proteosomal degradation of the target protein related to the transcriptional regulation of follistatin. In addition to the possible transcriptional regulation of follistatin by parkin, the activation of b-catenin observed in the HCC tissues might be attributable to enhanced expression of the follistatin gene, because it has been demonstrated that activation of b-catenin results in the induction of follistatin expression in various cancer cells (Willert et al., 2002; Germann et al., 2003) .
Our data showed that parkinÀ/À hepatocytes were significantly more resistant to cell death in association with the upregulation of follistatin. Follistatin is secreted, and is sometimes membrane associated, and exerts its effects as the most potent endogenous inhibitor of activin (Harrison et al., 2005) . Accumulating evidence suggests that the activin/follistatin system is involved in the regulation of hepatocyte proliferation and apoptotic cell death (Chen et al., 2002; Harrison et al., 2005; Rodgarkia-Dara et al., 2006) . Several animal models and analyses of clinical specimens revealed that deregulation of activin signaling, mainly achieved by follistatin upregulation, contributes to pathologic conditions such as hepatic inflammation, fibrosis and liver cancer (Rossmanith et al., 2002; Grusch et al., 2006; Patella et al., 2006) . Overexpression of activins induces hepatocyte apoptosis in vitro and in vivo (Schwall et al., 1993; Hully et al., 1994) , whereas follistatin administration decreased hepatocyte apoptosis in a hepatitis mouse model (Patella et al., 2006) . Furthermore, follistatin administration by intraportal infusion or adenovirusmediated overexpression stimulates DNA synthesis and liver growth in normal rat livers (Kogure et al., 2000; Takabe et al., 2003) . Experimentally induced rodent liver tumors, as well as human HCCs, show upregulated expression of follistatin (Grusch et al., 2006) . These findings suggest that deregulation of the balance between the expression of activins and their antagonist, follistatin, may contribute to the growth advantage of hepatocytes and result in liver cancer. Therefore, it is likely that upregulation of follistatin is associated with the development of HCC in parkinÀ/À mice.
In conclusion, our findings demonstrate that parkin is important in the regulation of hepatocyte proliferation and apoptosis, and that the loss of parkin expression might contribute to the overproliferation of hepatocytes, leading to hepatocarcinogenesis. Because b-catenin activation was specifically observed in the tumor, but not in the nontumorous region of the parkin-deficient livers, additional events for genetic changes might be required in the parkin-deficient liver to develop the HCC.
Materials and methods

Generation of parkinÀ/À mice
The mutant parkin allele lacking approximately 2 kb of the parkin exon 3 genomic sequence was generated in a mixed 129SV/C57BL6 (50/50) genetic background (Kitao et al., 2007) . Mice received humane care according to the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23).
Isolation and culture of mouse primary hepatocytes Mouse primary hepatocytes were obtained from 10-to 11-week-old mice by the two-step collagenase perfusion method (Seglen, 1976) . In brief, hepatocyte suspensions were obtained by passing collagenase type II (Gibco BRL, Life Technologies Inc., Rockville, MD, USA) digested liver through a 70 mm cell strainer, followed by centrifugation to collect the mature hepatocytes. After isolation, hepatocytes were resuspended in Dulbecco's modified Eagle's medium (DMEM; Gibco-BRL) supplemented with 10% fetal bovine serum and seeded on collagen type 1-coated dishes at a density of 8 Â 10 4 cells/cm 2 . The cells were maintained at 37 1C in a humidified atmosphere of 5% CO 2 .
siRNA duplexes composed of 25 nucleotide sense and antisense strands used for targeting follistatin were obtained Quantitative real-time RT-PCR RNA was extracted using Sepasol-RNA 1 Super (Nacalai Tesque, Kyoto, Japan). For the RT reaction, total RNA was reverse-transcribed into cDNA using the Superscript III first strand synthesis system and oligo-dT 12-18 primers (Invitrogen; Matsumoto et al., 2006) . PCR amplification was performed using Takara Ex Taq DNA polymerase (Takara, Tokyo, Japan). The oligonucleotide primers used in this study are shown in Supplementary Table 4 . Quantification of gene expression was performed by quantitative real-time RT-PCR using a 7300 Real-Time PCR system (PE Applied Biosystems, Foster City, CA, USA) and Platinum SYBR Green qPCR SuperMix UDG (Invitrogen) as described (Kou et al., 2006) . To assess the quantity of isolated RNA, as well as the efficiency of cDNA synthesis, target cDNAs were normalized to the endogenous mRNA levels of the housekeeping reference gene, 18S rRNA . For simplicity, the expression levels of the target gene were expressed relative to those of the control specimen. Human liver tissues for RT-PCR analyses were obtained from biopsy specimens of tumor tissues at the proximal edge of freshly resected specimens and frozen immediately in liquid nitrogen.
RNA preparation and hybridization to the microarray Total RNA was extracted from mice liver tissues using a RNA assay mini kit (Qiagen). First-strand cDNA was synthesized from 500 ng of total RNA in the presence of Cy5 or Cy3 dCTP. The Cy3-and Cy5-labeled samples derived from wildtype and parkinÀ/À mice at 72 weeks of age were injected simultaneously into the same spot of the whole mouse 60-mer oligo microarray (Agilent Technologies, Palo Alto, CA, USA). After hybridization at 65 1C for 17 h, the slides were washed with 6 Â SSC containing 0.005% Triton X-102, and dried using a nitrogen-filled air gun. Array image acquisition and feature extraction was performed using an Agilent G2565AA Microarray Scanner with feature extraction software (version 8.5.1.1; Agilent Technologies). Statistical evaluation was performed using the algorithm developed by Agilent for the array analysis. Genes that were upregulated or downregulated in tumorous and nontumorous liver tissues by more than fivefold compared to normal liver tissues and had P-values less than 0.05 were considered.
Immunoblotting analysis
Protein samples were separated by SDS-polyacrylamide gel electrophoresis (PAGE) 10% (w/v) polyacrylamide gels and subjected to immunoblotting analysis as described previously (Endo et al., 2007) . The polyclonal antibodies against mouse follistatin and a-tubulin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Calbiochem (San Diego, CA, USA), respectively.
Immunohistochemical staining analysis
Immunohistochemical staining was carried out according to a previously described protocol (Toda et al., 1999) . The polyclonal antibodies for PCNA, AFP and b-catenin were purchased from Santa Cruz Biotechnology, Dako Cytomation (Glostrup, Denmark) and Transduction Labs (Palo Alto, CA, USA), respectively.
Measurement of caspase activity and apoptosis assay
Liver tissues from the mice were prepared in buffer A (1 M KCl, 1 M MgCl 2 , 1M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 0.5 M EDTA and 10% CHAPS) and normalized for total protein content. A 30 mg sample of protein was incubated with either 10 ng of granzyme B (Calbiochem) or 0.5 nmol of cytochrome c (Sigma, St Louis, MO, USA) and 1 mM dATP at 37 1C for 30 min as described (Marusawa et al., 2003) . Then, 5 ml of reaction mixture was incubated with caspase-3 substrate Ac-DEVD-pNA (10 mM), and caspase activity was assessed using a colorimetric CaspACE assay system (Promega, Madison, WI, USA). For the measurement of caspase-3 activity, the plates were read at 405 nm using microplate reader (Molecular Devices Co., Tokyo, Japan). For the evaluation of cell death, mice primary hepatocytes were cultured in DMEM on collagen-coated dishes. After 24 h of isolation, cells were treated with either CDDP (200 mM), DOX (10 mM) or VP-16 (400 nM) for 48 h. Cell viability was determined by the trypan blue exclusion test (Marusawa et al., 2003) or the Annexin-VFluos apoptosis detection kit (Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer's instruction.
Flow cytometric analysis A total of 1 Â 10 5 cells were plated on 10 cm collagen-coated dishes. Two days after treatment with HGF (PeproTech, London, UK) at a concentration of 10 ng/ml, BrdU (20 mM; Roche, Basel, Switzerland) was added to the culture medium for 12 h. The cells were then fixed in 70% ice-cold ethanol and incubated at 4 1C overnight. Fluorescence was determined by using a FACScan flow cytometer (Becton Dickinson, Franklin Lake, NJ, USA) after adding propidium iodide. Data were acquired and analysed using CELLQuest software (Becton Dickinson).
Cell culture, transfection and reporter plasmid assay Human hepatoma-derived cell lines, Huh-7 and Hep3B were maintained in DMEM containing 10% fetal bovine serum. For plasmid transfection, we used Lipofectamine (Invitrogen) for Huh-7 and Trans-IT 293 (Mirus Bio Corporation) for Hep3B. To determine the promoter activity of the follistatin gene, the reporter plasmids were generated by inserting the PCRamplified 196-and 361-bp 5 0 -proximal promoter regions of the follistatin gene (de Groot et al., 2000) into the pGL-3 luciferase vectors (Promega). The reporter construct and pRL-TK (Promega) were then co-transfected with an expression plasmid-encoding parkin or control vector into NIH3T3 cells. The cell lysates were analysed for luciferase activity using the Dual-Luciferase Reporter Assay System (Promega; Tanaka et al., 2006) .
